Lansoprazole
As of the edition of 20 October 2026, Lansoprazole is a small molecule: marketed, first approved in 1990 (FR); acts on ATP4A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Small molecule
- Brand name
- Prevacid
- First approved
- 11 December 1990 (FR)
- Approvals on record
- 19 in 5 regions
- Holder of the most recent approval
- Dexcel Pharma Technologies; 5 holders in all
- Registered trials
- 121, 16 stopped early
- Disease areas
- Digestive system; Lungs and airways; Cancer; Immune system; Infections; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ATP4A | Potassium-transporting ATPase alpha chain 1 | P20648 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 18 | 12 | 3 | 2 |
| Phase 1 | 25 | 22 | 0 | 2 |
| Phase 2 | 15 | 10 | 1 | 3 |
| Phase 3 | 21 | 14 | 2 | 3 |
| Phase 4 | 42 | 27 | 1 | 6 |
| All trials | 121 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Takeda | Applicant and Lead sponsor of trials | 1993 to now |
| Tap Pharmaceutical | Applicant | 2004 to now |
| Novartis | Later holder and Lead sponsor of trials | 2006 to now |
| Dexcel Pharma Technologies | Later holder | 2016 to now |
| Perrigo Pharma International Designated Activity | Acquired holder | 2020 to now |